Opioid Use Disorder

Researchers observed a substantial reduction in filled naloxone prescriptions that exceeded a reduction in filled opioid prescriptions and filled prescriptions for any medication during the COVID-19 pandemic.

Patients with opioid dependence who received subcutaneous buprenorphine reported higher satisfaction and lower treatment burden vs. those who took sublingual buprenorphine, according to results of a randomized clinical trial.

HHS has released new practice guidelines to expand access to buprenorphine for opioid use disorder.

Even with health insurance, people with opioid use disorder receive lower quality preventive and chronic care as well as lower quality care coordination, according to results of a cross-sectional study.

Patients with substance use disorders who received navigation services in the hospital through 3 months after discharge had lower rates of ED readmission vs. those who received usual care, according to recent data from a single-center trial.

Benzodiazepine or Z-drug treatment was linked to increased risk for nonfatal drug-related poisoning among patients with opioid use disorder, according to results of a case-crossover analysis published in American Journal of Psychiatry.

A collaborative care model that utilizes buprenorphine-waivered physicians and community pharmacists was associated with high rates of opioid use disorder treatment retention and adherence, results of a pilot study showed.

Transgender adults have a higher prevalence of substance use disorder diagnoses compared with cisgender adults, according to a study published in JAMA Network Open.

HHS has released new guidance that the agency said will improve access to medication-assisted treatment for opioid use disorder.

From 2010 to 2017, estimated rates of neonatal abstinence syndrome and maternal opioid use disorder significantly increased across the United States, data show.